Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Xianbo Wu; Xinwei Yang; Qi Liang; Xiali Xue; Jianli Huang; Jie Wang; Yihua Xu; Rongsheng Tong; Maoyu Liu; Qiaodan Zhou; Jianyou Shi

doi:10.1016/j.ejmech.2021.113842

Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Eur J Med Chem. 2021 Dec 15:226:113842. doi: 10.1016/j.ejmech.2021.113842. Epub 2021 Sep 11.

Authors

Xianbo Wu¹, Xinwei Yang¹, Qi Liang², Xiali Xue³, Jianli Huang⁴, Jie Wang⁴, Yihua Xu⁵, Rongsheng Tong⁶, Maoyu Liu⁷, Qiaodan Zhou⁸, Jianyou Shi⁹

Affiliations

¹ School of Sports Medicine and Health, Chengdu Sport University, Chengdu Sichuan, 610041, China.
² College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, 610031, China.
³ Institute of Sports Medicine and Health, Chengdu Sport University, Chengdu Sichuan, 610041, China.
⁴ Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou, 550002, China.
⁵ Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan, 611137, China.
⁶ Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu Sichuan, 610072, China.
⁷ Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan, 611137, China. Electronic address: liumaoyu126@126.com.
⁸ Ultrasonography Lab, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu Sichuan, 610072, China. Electronic address: 970711848@qq.com.
⁹ Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu Sichuan, 610072, China. Electronic address: shijianyoude@126.com.

PMID: 34536672
DOI: 10.1016/j.ejmech.2021.113842

Abstract

Glaucoma is the third leading cause of blindness and impairment of vision worldwide, after refractive errors and cataracts. According to the survey, the number of people with glaucoma is more than 76 million, with projections increasing to 112 million by 2040. With the coming of an aging society, the number of people suffering from glaucoma will increase day by day. Glaucoma is a heterogeneous disease characterized by damage to the head of the optic nerve and visual field. High intraocular pressure is a major risk and cause of glaucoma optic neuropathy. Therefore, drug lowering intraocular pressure therapy is still the first-line therapy in clinical practice. Here, the targets, structure-activity relationship, and clinical progress of drugs for the treatment of glaucoma are reviewed.

Keywords: Drug treatment; Glaucoma; High intraocular pressure; OHT.

Publication types

Review

MeSH terms

Cell Survival / drug effects
Drug Design*
Glaucoma / drug therapy*
Glaucoma / pathology
Humans
Intraocular Pressure / drug effects
Molecular Structure
Ophthalmic Solutions / chemical synthesis
Ophthalmic Solutions / chemistry
Ophthalmic Solutions / pharmacology*

Substances

Ophthalmic Solutions